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A b s t r a c t  
Development of new drug candidates and novel delivery techniques for treatment of ocular 
diseases has recently accelerated. The field of ocular drug delivery is one of the most 
interesting and challenging endeavors facing the pharmaceutical scientist for past 10-20 
years. In ophthalmic formulation to the eye like solutions, suspensions, and ointments are 
available in the market shows drawbacks such as increased precorneal elimination, 
blurred vision and high variability in efficiency. The major setback associated with the 
conventional dosage forms is the bioavailability of drug. In the last three decades to 
improve the bioavailability by common to adding viscosity-enhancing agents or 
mucoadhesive polymers into dosage formulations. To prevail over to conventional dosage 
formulations there were non-conventional technologies such as lipososme, niosome, 
microspheres, nanoparticle, implant, gene therapy and ocular inserts could be developed 
in pharmaceutical market. In this article, we have summarized the different types of 
commonly used ophthalmic formulations and compared the conventional formulations with 
the advanced formulation in many respects like their applicability, acceptance, 
characteristics and utility. 
„Ocular drug delivery is one of the most interesting and challenging endeavours facing the 
pharmaceutical scientist...The anatomy, physiology and biochemistry of the eye render this 
organ exquisitely impervious to foreign substances...The challenge to the formulator is to 
outwit the protective barriers of the eye without causing permanent tissue damage...The 
ancient ophthalmic solutions, suspensions and ointment dosage forms are clearly no 
longer sufficient to combat some present virulent diseases...‰ 
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Introduction 
Many people suffer from a wide variety of ocular diseases, many 
of which lead to visual impairment and ocular blindness. Certain 
ocular diseases are quite rare, whereas others, such as cataracts, 
age-related macular degeneration (AMD), and glaucoma, are very 
common, especially in the aging population (Table 1). A rapid 
development of new technologies in ocular drug delivery and new 
drug candidates, including biologics, to treat these challenging 
diseases in the anterior and posterior segments of the eye have 
recently emerged [1]. For development of new drug candidates 
and novel delivery techniques for treatment of ocular diseases 
has recently accelerated. Controlled drug delivery to the eye is  
 
 
 
restricted due to these limitation imposed by the efficient 
protective mechanism. Ideal ocular drug delivery must be able to 
sustain the drug release and to remain in the vicinity of front of the 
eye for prolong period of time. Consequently it is imperative to 
optimize ocular drug delivery, one of the way to do so is by 
addition of polymers of various grades, development of viscous 
gel, development of colloidal suspension or using erodible or non 
erodible insert to prolong the precorneal drug retention. More 
efficient ocular delivery systems that have been commercialised 
recently and are still under evaluation aim at enhancing the drug 
bioavailability either by providing prolonged, sustained delivery to 
the eye or by facilitating transcorneal penetration. 
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Ocular Drug Absorption 
Absorption of drugs takes place either through corneal or 
noncorneal routes.  The noncorneal route involves absorption 
across the sclera and conjuctiva into the intraocular tissues.  This 
route is, however, not productive as it restrains the entry of drug 
into aqueous humour.  Maximum absorption thus takes place 
through cornea, which leads the drug into aqueous humour. The 
goal of oular drug delivery systems has traditionally been to 
maximize ocular drug absorption rather than to minimize systemic 
absorption [2,3]. 
Solutions are undoubtedly the most commonly used and accepted 
forms. They are relatively simple to make, filter and sterilise. The 
factors that must be taken into account while formulating aqueous 
solution include selection of appropriate salt of the drug 
substance, solubility, therapeutic concentration required, ocular 
toxicity, pKa, and the effect of pH on stability and solubility, 
tonicity, buffer capacity, viscosity, compatibility With other 
formulation ingredients as well as packaging components, choice 
of preservative, ocular comfort and ease of manufacturing. The 
stability of ophthalmic solutions and other dosage forms 
determine the shelf life and expiration dating of the product. 
Suspensions, while not as common as solutions, are 
widely used for formulations involving anti-inflammatory steroids 
(for example prednisolone 
alcohol and acetate). In most ophthalmic suspension, the average 
particle size is less than 10 μm. The most efficient method of 
producing such particle size is by dry milling. However, we milling 
may be desirable for potentially explosive ingredients. Other 
methods of particle size reduction include micro-pulverization, 
grinding, and controlled precipitation. An ophthalmic suspension 
contains many inactive ingredients such as dispersing and wetting 
agents, suspending agents, buffers and preservatives. In case 
ointments are still being marketed for night time applications and 
where extended therapeutic actions are required [4, 5]. A major 
disadvantage of the ophthalmic ointments is that they cause 
blurred vision due to refractive index difference between the tears 
and the non-aqueous nature of the ointment and inaccurate 
dosing. This approach relies on vehicles containing polymers that 
adhere via non-covalent bonds to conjunctival mucin, thus 
ensuring contact of the medication with the precorneal tissues 
until mucin turnover causes elimination of the polymer 
Mucoadhesive polymers can provide a localized delivery of an 
active agent to a specific site in the body such as the eye. Such 
polymers have a property known as bioadhesion meaning 
attachment of a drug carrier to a specific biological tissue such as 
the epithelium and possibly to the mucosal surface of such 
tissues. These polymers are able to extend the contact time of the 
drug with the biological tissues and thereby improve ocular 
bioavailability. There are several bioadhesive polymers now 
available with varying degree of mucoadhesive performance 
Carboxymethylcellulose, Carbopol, Carbopol and hydroxypropyl 
cellulose [6]. 
Vesicular and Particulate  
Liposomes and Niosomes 
In recent years, vesicles have become the vehicle of choice in 
drug delivery. Lipid vesicles were found to be of value in 
immunology, membrane biology, diagnostic techniques, and most 
recently, genetic engineering. In vesicular dosage forms, the drug 
is encapsulated in lipid vesicles, which can cross cell membrane. 
Vesicles, therefore, can be viewed as drug carriers and as such 
they change the rate and extent of absorption as well as the 
disposition of the drug. Vesicular drug delivery systems used in 
ophthalmics broadly include liposomes and Niosomes. 
Microspheres and Nanoparticles 
Particulate polymeric delivery systems include microspheres and 
nanoparticles. The difference between these systems is based on 
their size. Particles in the micrometer size (>1 um) are called 
microspheres whereas those in the range of <1 μm are known as 
nanoparticles. This discrimination is useful because of their 
different biological and physicochemical behaviors. Although, 
there are no marketable sterile ophthalmic products based on 
these systems, their potential in the ocular field, particularly in 
delivering the drug to the back of the eye in the retinal space is 
quite exciting. These particles are either biodegradable such as 
polylactic acid (PLA) and polyglycolic acids (PLGA) or 
nonbiodegradable such as poly (alkyl cyanoacrylate), poly (butyl 
cyanoacrylate), isobutyl cyanoacrylate, cellulose acetate 
phthalate, poly (ethyl cyanoacrylate) and poly (hexadecyl 
cyanoacrylate). For retinal drug delivery biodegradable polymers 
are preferable and in most cases required. Both lactic acid and 
glycolic acids are biodegradable and they produced and 
eliminated by the body. These polymers decompose into carbon 
dioxide and water. The manufacture of sterile microspheres and 
nanoparticles is more complicated as compared to conventional 
dosage forms such as aqueous solutions and suspensions. 
Several manufacturing processes such as milling and 
homogenization techniques, supercritical fluid technology and 
emulsion technology been developed over the years [7,8].  
Prodrugs 
Prodrugs are chemical modifications of known pharmacological 
agents. These drugs, when administered to biological systems, 
are biotransformed to the parent compound. In the past, 
epinephrine has been routinely used to control ocular 
hypertension. However, due to its chemical structure, it does not 
have optimal ocular bioavailability characteristics. 
A prodrug of epinephrine namely, dipivefrin (DPE) has been 
developed successfully for several years. Some key advantages 
of such prodrugs are (a) enhanced bioavailability (b) increased 
potency (c) lower dose (d) prolonged duration of action (e) reduce 
side effects and (f) enhanced chemical stability. The lipophilic 
nature of DPE responsible for its greater bioavailability in ocular 
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tissues. DPE at 0.1% concentration produces intraocular pressure 
lowering response which is clinically comparable to 2% 
epinephrine while showing greatly reduced ocular tolerance and 
no cardiovascular effects. 
Controlled ocular drug delivery  
Ocular insert 
Ocular insert defined as sterile preparation with solid or semisolid 
consisting and whose size and sharp are especially designed for 
ophthalmic application. They offer several advantages as increase 
ocular residence, possibility of releasing drug at a slow constant 
rate, accurate dosing and increased shelf life with respect to 
aqueous solutions. Ocusert, pilocarpine ocular therapeutic system 
is the first product marketed by Alza incorporation USA from this 
category. Two types of Ocuserts are available in the market. 
Collegen shields used in animal models and in humans by 
Bloomfield et al. credits for first suggesting in 1977 and in 1978 
use of collgen inserts as tear substitution and as delivery system 
for gentamicin. Saettone et al. evaluated series of commercially 
available polymers as possible material for the preparation of 
soluble, monolithic insert. Various polymers tried in ocular inserts 
were polyacrylic acid, polyvinyl alcohol, silicone elastomer, 
hydroxy propyl cellulose, ethyl cellulose cellulose acetate 
phthalate and polymethylacrylic acid, hyluronic acid [9, 10, 11]. 
 
These devices might present valuable advantages, such as: 
Ć Increased ocular permanence with respect to standard vehicles, 
hence prolonged drug activity 
and a higher drug bioavailability; 
Ć Accurate dosing (theoretically, all of the drug is retained at the 
absorption site); 
Ć Capacity to provide, in some cases, a constant rate of drug 
release; 
Ć Possible reduction of systemic absorption, which occurs freely 
with standard eye-drops via the nasal mucosa; 
Ć Better patient compliance, resulting from a reduced frequency of 
medication and a lower incidence of visual and systemic side 
effects; 
Ć Possibility of targeting internal ocular tissues through non-
corneal conjunctival scleral penetration routes; and 
Ć Increased shelf life with respect to eye-drops due to the absence 
of water. 
Ocular inserts have been developed in which the drug is delivered 
based on diffusional mechanisms. It delivers the drug at constant 
rate minimizing side effects by avoiding excessive absorption. 
One popular product is Ocusert which delivers pilocarpine.  
Uses: This medication is a tear-like substance used in the 
treatment of dry eye syndromes. 
How to Use: The inserts are to be properly placed in the eye once 
or twice daily as directed. Your doctor will demonstrate how to 
place the insert into the eye and how to remove it. Practice 
inserting and removing the insert while in the doctor's office so 
any questions you have can be answered. 
Side Effects: Vision may be temporarily blurred or unstable for a 
period after applying the insert. Use caution if driving or 
performing duties requiring clear vision. Eye irritation or 
discomfort, sticking of eyelashes and sensitivity to bright light may 
occur when first using this medication. If these symptoms 
continue or become worse, inform your doctor. Notify your doctor 
immediately if you develop: itching, pain burning, and redness, 
swelling in or around the eyes, vision problems. If you notice other 
effects not listed above, contact your doctor or pharmacist. 
Precautions: Tell your doctor if you have any of the following 
conditions: eye problems, any allergies. As with any medication, 
this should be used cautiously during pregnancy or while breast-
feeding. Discuss the risks and benefits with your doctor. 
Drug Interactions: Tell your doctor of any over-the-counter or 
prescription medication you may take. Do not start or stop any 
medicine without doctor or pharmacist approval. 
Missed Dose: Each insert is to be used for a 24 hour period. If 
you forget to replace an insert, do it as soon as remembered. Do 
not "double-up" the dose to catch up. 
Storage: Store at room temperature between 59 and 86 degrees 
F (15 and 30 degrees C) away from heat. Check the expiration 
date on the box and discard any expired medication. 
Currently Available Insert for Ocular Drug 
Delivery System  
Implants  
Biodegradable Matrix Implants 
Biodegradable Matrix implants are typically used to treat acute-
onset diseases that require a loading dose followed by tapering 
doses of the drug during a 1-day to 6-month time period. They are 
most commonly made from the copolymers polylactic acid (PLA) 
and/or poly-lactic-glycolic acid (PLGA), The release of drug 
generally follows first-order kinetics with an initial burst of drug 
release followed by a rapid decline in drug levels. The advantage 
over a nonbiodegradable implant is that biodegradable implants 
do not require removal, as they dissolve over time [12]. 
Biodegradable implants also allow flexibility in dose and treatment 
from short duration (weeks) to longer duration (months to a year), 
depending on the polymer PLA/PLGA ratio, which is another 
benefit in tailoring drug delivery to disease progression, because 
dose and treatment requirements may change over time. Effective 
sustained delivery has been achieved using a variety of drugs: 
antiviral, antifungal, antimetabolic, immunosuppressive agents, 
and steroids. A biodegradable matrix implant consisting of PLGA 
and up to 700 μg dexamethasone (Posurdex) drug-delivery 
system (DDS) has been evaluated in patients with persistent 
macular edema in phase 2 trials.The implant releases 
dexamethasone for up to 6 months in nonclinical studies after 
insertion into the vitreous through an innovative special injector 
and does not disturb the clear media [13]. 
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Non biodegradable (Reservoir) Implants 
Non biodegradable Reservoir implants are typically made with a 
pelleted drug core surrounded by nonreactive substances such as 
silicon, ethylene vinyl acetate (EVA), or polyvinyl alcohol (PVA); 
these implants are nonbiodegradable and can deliver continuous 
amounts of a drug for months to years. One of the first reservoir 
implants to gain Food and Drug Administration (FDA) approval 
was Vitrasert ganciclovir intraocular implant for treatment of 
cytomegalovirus retinitis in patients with acquired 
immunodeficiency .The Vitrasert implant is fixed and it releases 
the drug for 5 to 8 months.  
Advanced ocular drug delivery  
Gen delivery and Scleral Plug  
Technologies for drug, gene delivery for the treatment of diseases 
of the back of the eye. It will integrate the topics of 
nanotechnology; current and emerging drug and gene delivery 
systems; and smart delivery strategies to address current 
challenges and future opportunities in treating blinding diseases. 
With the identification of new therapeutic agents such as siRNA, 
miRNA and gene therapies, the need for the development of 
novel delivery systems also escalates. Several nucleic acid 
therapies may fail due to the lack of availability of appropriate 
delivery systems that can: 
Protect the therapeutic agent from degradation by nucleases, 
Allow enhanced cellular entry, 
Minimize off-target effects, 
Offer prolonged delivery in treating chronic retinal disorders. 
Most blinding diseases progress over several decades, therefore 
even with successful protein therapeutic agents, frequent 
injections throughout several years might be detrimental to retinal 
health. This limitation can potentially be overcome through the 
development of long-term delivery approaches for protein drugs. 
The entrapment of immunologically isolated cells with hollow 
fibres or microcapsules before their administration into the eye is 
called Encapsulated Cell Technology (ECT) which enables the 
controlled, continuous, and long-term delivery of therapeutic 
proteins directly to the posterior regions of the eye. Along with 
tissue engineering, gene therapy approaches stand on the front 
line of advanced biomedical research to treat blindness arising 
from corneal diseases, modified human RPE cells secretes ciliary 
neurotrophic factor into the vitreous humour of the patientsÊ eyes. 
ECT can potentially serve as a delivery system for chronic 
ophthalmic diseases like neuroprotection in glaucoma, anti-
angiogenesis in choroidal neovascularization, anti-inflammatory 
factors for uveitis. Several kinds of viruses including adenovirus, 
retrovirus, adeno-associated virus, and herpes simplex virus, 
have been manipulated for use in gene transfer and gene therapy 
applications 
 
 
Scleral plug can be implanted using a simple procedure at the 
pars plana region of eye, made of biodegradable polymers and 
drugs, and it gradually releases effective doses of drugs for 
several months upon biodegradation. The release profiles vary 
with the kind of polymers used, their molecular weights, and the 
amount of drug in the plug. The plugs are effective for treating 
vitreoretinal diseases such as proliferative vitreoretinopathy, 
cytomegalovirus retinitis responds to repeated intravitreal 
injections and for vitreoretinal disorders that require vitrectomy 
[14,15].  
Conclusion  
Nonstop progress in the understanding of principles and 
processes leading ocular drug absorption and disposition and 
continuing technological advances have surely brought some 
improvements in the efficacy of ocular drug delivery systems. 
However, ocular drug delivery still faces the challenges 
enunciated by (Lee and Robinson) several years ago. The most 
widely developed drug delivery system is represented by the 
conventional and non-conventional ophthalmic formulations to 
polymeric nanoparticle, microemulsions, implant, and ocular 
inserts. At present very few new ocular drug delivery systems 
have been commercialized in which them ocular inserts have 
been mostly used. In future an ideal system should be able to 
achieve an effective drug concentration at the target tissue for an 
extended period of time, while minimizing systemic exposure and 
the system should be both comfortable and easy to use. 
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Table 1 Leading causes of visual impairment and ocular discomfort 
S.No Disease Number of Patients 
1 Cataract 6ă19% of patients older than 43 years 
2 Age-related macular 11ă28% of patients older than 65 years 
3 Glaucoma 1ă4% of patients older than 45 years 
4 Diabetic retinopathy 71ă90% of diabetics older than 10 years 
5 Dry eye 50ă60 million (10ă15% of U.S. 
population) 
6 Ocular allergy ~25% of U.S. population
 
Table 2 Approaches Developed On Ocular Drug Delivery 
S. 
NO 
DOSAGE FORMS ADVANTAGES DISADVANTAGES 
1.  Polymeric solutions  Increased residence time Increased corneal penetration of drug 
Rapid initial drainage rate Bioavailability is valid in 
animals but minimal in humans. 
2.  Phase transition systems Gel at physiological pH comfortable, Less blurred 
vision than ointment 
No rate control on diffusion 
Matted eyelids after use 
3.  Suspensions Patient compliance, Best for drugs with slow dissolution. 
Drug properties decide performance Loss of both 
solution and suspended solid. 
4.  Ointments Flexibility in drug choice Improved drug stability Drug choice limited by partition co-efficientNo true sustaining effect 
5.  Ocular penetration 
enhancers  
Increased bioavailability of peptides & proteins Physiochemical properties of the drug
Tissue irritation and damage 
6.  Emulsions Prolonged release of drug from vehicle 
Enhanced pulsed entry 
Patient non compliance 
Blurred vision 
Possible oil entrapment 
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7.  Bioadhesives Increased corneal contact time Water soluble polymers face the disadvantage of 
having a short half - life. 
8.  Collagen shields 
Simple and convenient Drug concentration 
achieved higher levels in the cornea and aqueous 
humour 
Discomfort 
Application of shield requires to anesthetize the cornea 
9.  Nanoparticles  Patient acceptance
Prolonged sustained release of drug 
Rapid disappearance from tear poor
Costly and technological difficulties. 
10.  
Vesicular systems (such as 
liposomes, niosomes, 
pharmacosomes,) 
No tissue irritation & drainage. Patient compliance
Prolonged sustained release of drug. Biocompatible  
& increased residence 
Limited drug loading 
Unstable due to hydrolysis of phospholipids 
Costly and technological difficulties. 
Table 3: Currently Available Insert for Ocular Drug Delivery System 
Drug 
Types of insert Transporter 
Anti  glaucoma 
Timolol  Soluble HPC,EudragitsRS100 
Timolol  Soluble/Bioerodible HPC;PVA;Carbopol 
Timolol and prodrug of Timolol Soluble/ Bioerodible HPC;PVA;Carbopol 
Timolol  Soluble HPMC
Pilocarpine Soluble HPC/D-Lactose , EudragitsRS100 
Pilocarpine Soluble PVA,XG,HPMC, EudragitsRS100 
Pilocarpine Soluble MC,Alginate
Pilocarpine Soluble HA,HAE
Pilocarpine Soluble HPC,PVM/MA
Pilocarpine Bioerodible PVMMA
Pilocarpine Bioerodible Gelatin
Pilocarpine Insoluble (Contact Lens) HEMM/EGDM
Pilocarpine Insoluble (Contact Lens) TEGDMA/MM
Pilocarpine Insoluble (Osmotic) Ethylene vinyl acetate  
Pilocarpine Insoluble
Anti Bacterial   
 
Soluble 
 
PVA 
 
Chloramphenicol 
Tobramycine /Chloramphenicol Soluble Collagen
Tetracycline /Chloramphenicol Insoluble (Contact Lens) PMM
Gentamicin Soluble Collagen
Gentamicin Soluble Collagen
Gentamicin Soluble HPC,EC, Carbopol 
Gentamicin Bioerodible Gelatin
Erythromycine Soluble Copolymers of Nvinylpyrrolidone 
Antiviral Bioerodible Polypeptide
Idoxuridine 
Trifulurothymidine Soluble Collagen
Antiinflammatory  
Soluble PVA,HPC,EC,CAP,Eudragit Dexamethasone 
Dexamethasone Soluble Collagen
Dexamethasone Bioerodible Gelatin
Perdnisolone acetate Soluble Collagen
Perdnisolone Insoluble (Contact Lens) HEM, N vinylpyrrolidone 
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Figure 1: Ocular Drug Absorption 
 
 
Figure 2: Advance Approaches to Ocular Drug Delivery System 
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